New Features information at Pharmaceutical Technology New and updated information from Features listed on en-us New Features information at Pharmaceutical Technology Pharma Technology Focus – Issue 57 In this issue: Japan’s pharma industry looks abroad, Trump’s plans for US drug manufacturing, unlocking regenerative medicine, the medical benefits of turmeric, the dangers posed by first-in-human drug trials, and more. Wed, 22 Mar 2017 14:44:00 GMT Turning to turmeric: exciting drug candidate or another dead end? Turmeric has long been used as a natural remedy, and many studies seem to back that up. However, a recent review has suggested that many of the apparent benefits are bad science. So what does that mean for turmeric research, and particularly for the … Mon, 20 Mar 2017 00:00:00 GMT BlueRock Therapeutics: Ontario’s home-grown stem cell contender New Toronto-based regenerative medicine biotech BlueRock Therapeutics was launched in December with a massive $225m series A financing from Bayer and Versant Ventures. What stem cell-based therapies is the company working on to justify this investor … Tue, 14 Mar 2017 00:00:00 GMT Takeda turns its focus overseas Japanese pharmaceutical company Takeda has bought Ariad Pharmaceuticals for around $5.2bn. Deals of this kind are becoming increasingly prevalent, as the Japanese pharma industry sets its sights beyond the traditional domestic market. Abi Millar repo… Mon, 13 Mar 2017 00:00:00 GMT Learning from tragedy: safety and dosing in first-in-human trials The Rennes clinical trial disaster in January last year highlights the dangers posed by first-in-human trials of high-risk drug candidates, with dosing strategies coming under the spotlight. What makes early-stage trials go wrong, and how can dosing … Wed, 08 Mar 2017 00:00:00 GMT February's top stories: Takeda's $5.2bn acquisition, Sanofi €270m cell culture facility investment Takeda completed its acquisition of American oncology company ARIAD Pharmaceuticals for $5.2bn, while Sanofi and Lonza invested €270m in a new mammalian cell culture facility in Switzerland. wraps up the key headlines fr… Tue, 07 Mar 2017 00:00:00 GMT Is US drug manufacturing homeward bound? New US President Donald Trump has indicated that he wants to reform drug manufacturing for the US market, emphasising domestic production rather than outsourcing to plants abroad. Abi Millar looks into the US’s current pharma manufacturing and drug s… Mon, 06 Mar 2017 00:00:00 GMT Using shark antibodies to treat Alzheimer’s disease Dutch biotech company Crossbeta Biosciences has been granted an exclusive license to three beta-amyloid oligomer (AßO)-specific shark antibodies, identified under a collaboration with Australian company AdAlta. These ‘i-bodies’ are considered to have… Thu, 02 Mar 2017 00:00:00 GMT How an Alzheimer’s drug turned tooth regenerator could unlock regenerative medicine Researchers at King’s College London have found a new use for an Alzheimer’s drug: repairing teeth. Elly Earls meets Professor Paul Sharpe, lead researcher on the study, to find out what implications this surprising discovery has for dentistry and be… Mon, 27 Feb 2017 00:00:00 GMT Moving mountains: balancing safety and speed in drug development The speedy review of urgently needed medicines is a key objective of any drug regulatory body, as is maintaining high safety standards. But what is the right balance between the two, and what can we learn from major public health crises and the pract… Mon, 27 Feb 2017 00:00:00 GMT Medicines Discovery Catapult: improving collaborative drug discovery in the UK The Medicines Discovery Catapult, one of 11 technology and innovation centres established by Innovate UK, has been set up to enable new, collaborative means of drug discovery. Abi Millar spoke to CEO Chris Molloy to find out more. Thu, 23 Feb 2017 00:00:00 GMT Therapeutic orphans: child-friendly drugs and the quest for adherence Most drugs are developed for adults, which poses real difficulties when the afflicted patients are children and often leads to very poor adherence. So, what needs to be done to make sure drugs are suitable and tolerable for children? A landmark initi… Tue, 21 Feb 2017 00:00:00 GMT Nigeria’s HIV ‘breakthrough’: separating truth from hope A Nigerian researcher’s claim to have developed a ‘cure’ for HIV has been enthusiastically received by local media, but the country’s top AIDS and disease control organisations have pointed out myriad flaws in the data. What can the ongoing debate ov… Mon, 20 Feb 2017 00:00:00 GMT A peptide to prevent pre-diabetes An Irish biotech start-up has joined the global battle against diabetes with an unexpected weapon of choice: food. Elly Earls meets the company’s founder and chief scientific officer Dr Nora Khaldi to find out more. Thu, 16 Feb 2017 00:00:00 GMT Pharma Technology Focus – Issue 56 In this issue: Clinical research in the UK, fighting diabetes with peptides, balancing speed and safety when reviewing new drugs, the potential of shark antibodies to treat Alzheimer’s, Elsevier’s new project to boost innovation, and more. Wed, 15 Feb 2017 15:57:00 GMT Why the UK NHS needs clinical research New data published by the UK’s National Institute for Health Research has revealed that for the first time ever, all NHS Trusts in England are engaged in clinical research. Abi Millar finds out why, at such a testing time for the NHS, a strong clinic… Mon, 13 Feb 2017 00:00:00 GMT The Hive: new incubator makes a beeline for non-traditional pharma companies Elsevier’s new incubator project aims to highlight and bolster the incredible innovation taking place within pharmaceutical and biotech start-ups. Elly Earls catches up with Elsevier and two of the companies involved to find out more about The Hive a… Tue, 07 Feb 2017 00:00:00 GMT BenevolentAI: using artificial intelligence to speed up drug discovery British artificial intelligence company BenevolentAI recently signed an exclusive license agreement for a series of novel clinical stage drug candidates with Johnson & Johnson. Their potential was evaluated using the company’s unique AI technology, w… Tue, 07 Feb 2017 00:00:00 GMT January's top stories: J&J to acquire Actelion for $30bn, Takeda to acquire ARIAD for $5.2bn J&J agreed to acquire Swiss biotech company Actelion for $30bn, and Japan’s Takeda agreed to acquire US cancer drug manufacturer ARIAD for $5.2bn. wraps up the key headlines from January. Mon, 06 Feb 2017 00:00:00 GMT Tapping digital technologies to improve drug adherence Digital connected technologies are increasingly being used to improve patient adherence, one of the biggest challenges facing the healthcare system today. To find out more, Elly Earls talks to smart packaging developer Mevia and Internet of Things se… Mon, 23 Jan 2017 00:00:00 GMT